Table 2.
Differences in clinical and laboratory characteristics at discharge among patients receiving HD vs. patients receiving LD of intravenous furosemide.
| HD (n = 71) | LD (n = 50) | p-Value | |
|---|---|---|---|
| Laboratory data after treatment | |||
| Creatinine (mg/dL) | 1.60 (1.30–2.20) | 1.40 (1.16–1.50) | 0.006 |
| eGFR (ml/min/1.73 m2) | 40 (33–51) | 47 (42–56) | 0.008 |
| Serum sodium (mEq/L) | 138 (135–142) | 138 (136–140) | 0.81 |
| Serum potassium (mEq/L) | 4.0 (3.8–4.4) | 3.8 (3.6–4.3) | 0.28 |
| BNP (pg/mL) | 620 (381–824) | 610 (378–928) | 0.79 |
| Urine output (ml/die) | 2200 (1700–2700) | 2000 (1800–2500) | 0.57 |
| Additional hypertonic saline solution (%) | 41 | 20 | 0.02 |
| Inotropes agents administration (%) | 34 | 14 | 0.01 |
| WRF (%) | 29 | 28 | 0.98 |
| Persistence of congestion after treatment (%) | 25 | 34 | 0.30 |
| 180 days outcome events occurrence (%) | 75 | 22 | <0.001 |
| DR day 1 | 0.20 (0.00–0.32) | 0.33 (0.00–0.64) | 0.17 |
| DR day 2 | 0.106 (0.053–0.213) | 0.222 (0.127–0.407) | <0.001 |
| DR entire infusion period | 0.106 (0.064–0.240) | 0.266 (0.200–0.400) | <0.001 |
Abbreviations: B-type natriuretic peptide (BNP); diuretic response (DR); estimated glomerular filtration rate (eGFR); high dose (HD); low dose (LD).